| Indicators | Browse All

Azitra, Inc. (AZTR)

Healthcare | Biotechnology | Branford, United States | NYSE American
0.13 USD -0.01 (-8.380%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:32 a.m. EDT

The immediate outlook is severely clouded by a catastrophic multi-year price collapse. Despite a recent surge driven by a CEO-backed financing round and positive news regarding a cosmetic peptide program, the stock has lost nearly 99.8% of its value over the last two years, trading at a fraction of its historical worth. This massive drawdown reflects a market verdict that the company's current cash burn—evidenced by significant negative operating and free cash flows—and lack of profitability are unsustainable without further dilution. While the balance sheet currently shows low debt relative to equity, the relentless downward pressure suggests investors are pricing in a high probability of further capital raising or operational failure. There is no dividend to provide income, and the statistical models offer no reliable short-term directional edge given the extreme volatility and low confidence scores. The recent price jump appears to be a temporary reaction to liquidity events rather than a reversal of the fundamental deterioration.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.254295
MSTL0.259319
AutoARIMA0.309506
AutoTheta0.344179

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 29%
H-stat 3.82
Ljung-Box p 0.000
Jarque-Bera p 0.159
Excess Kurtosis -0.65
Attribute Value
Sector Healthcare
Debt to Equity Ratio 3.276
Market Cap 2,106,636
Forward P/E -0.25
Beta -1.21
Previous Name Azitra Inc
Website https://azitrainc.com

Info Dump

Attribute Value
52 Week Change -0.90657896
Address1 21 Business Park Drive
All Time High 1,036.0
All Time Low 0.1
Ask 0.13
Ask Size 4,500
Average Daily Volume10 Day 1,867,950
Average Daily Volume3 Month 11,645,022
Average Volume 11,645,022
Average Volume10Days 1,867,950
Beta -1.205
Bid 0.0
Bid Size 1,100
Book Value 0.647
City Branford
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.1301
Current Ratio 6.943
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 0.142
Day Low 0.1295
Debt To Equity 3.276
Display Name Azitra
Ebitda -11,658,645
Ebitda Margins 0.0
Enterprise To Ebitda 0.652
Enterprise Value -7,601,037
Eps Forward -0.52
Eps Trailing Twelve Months -0.87
Esg Populated 0
Exchange ASE
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.2033
Fifty Day Average Change -0.0732
Fifty Day Average Change Percent -0.36005905
Fifty Two Week Change Percent -90.6579
Fifty Two Week High 1.62
Fifty Two Week High Change -1.4899
Fifty Two Week High Change Percent -0.9196913
Fifty Two Week Low 0.1
Fifty Two Week Low Change 0.030099995
Fifty Two Week Low Change Percent 0.30099994
Fifty Two Week Range 0.1 - 1.62
Financial Currency USD
First Trade Date Milliseconds 1,686,922,200,000
Float Shares 12,126,517
Forward Eps -0.52
Forward P E -0.2501923
Free Cashflow -6,696,973
Full Exchange Name NYSE American
Full Time Employees 13
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.28419
Held Percent Institutions 0.06271
Implied Shares Outstanding 16,192,438
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,755,734,400
Last Split Factor 15:100
Long Business Summary Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Long Name Azitra, Inc.
Market us_market
Market Cap 2,106,636
Market State PRE
Max Age 86,400
Message Board Id finmb_404021170
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -11,814,265
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,106,636
Number Of Analyst Opinions 2
Open 0.14
Operating Cashflow -10,629,667
Operating Margins 0.0
Payout Ratio 0.0
Phone 203 646 6446
Pre Market Change -0.0032000095
Pre Market Change Percent -2.431618
Pre Market Price 0.1284
Pre Market Time 1,784,023,450
Prev Name Azitra Inc
Previous Close 0.142
Price Hint 4
Price To Book 0.2010819
Profit Margins 0.0
Quick Ratio 6.585
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0119
Regular Market Change Percent -8.38029
Regular Market Day High 0.142
Regular Market Day Low 0.1295
Regular Market Day Range 0.1295 - 0.142
Regular Market Open 0.14
Regular Market Previous Close 0.142
Regular Market Price 0.1301
Regular Market Time 1,783,972,800
Regular Market Volume 1,812,272
Return On Assets -0.81789
Return On Equity -1.5871
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 16,192,438
Shares Percent Shares Out 0.0172
Shares Short 278,208
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 61,636
Short Name Azitra Inc
Short Percent Of Float 0.026300002
Short Ratio 0.01
Source Interval 15
State CT
Symbol AZTR
Target High Price 1.0
Target Low Price 0.55
Target Mean Price 0.775
Target Median Price 0.775
Total Cash 10,051,003
Total Cash Per Share 0.621
Total Debt 343,330
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.87
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 0.310425
Two Hundred Day Average Change -0.18032502
Two Hundred Day Average Change Percent -0.5808972
Type Disp Equity
Volume 1,812,272
Website https://azitrainc.com
Zip 6,405